VectorY Therapeutics has added 74.5 million euros (83.5 million dollars) to its Series A financing, the Amsterdam company announced on November 11. The package includes a 30 million euro convertible loan from the European Investment Bank, supported by the European Commission’s InvestEU program. New investors Angelini Ventures and Invest-NL joined returning backers Forbion, EQT Life Sciences, Eli Lilly, Merck & Co.’s MRL Ventures, Insight Partners and BioGeneration Ventures. The extension builds on the 129 million euro Series A raised in November 2023 and takes VectorY’s reported financing to 234.5 million euros since its 31 million euro seed round in 2021.
The money is pointed at VTx-002, a gene therapy designed to make cells in the central nervous system produce antibodies against abnormal TDP-43, the protein that accumulates in motor neurons in up to 97 percent of ALS patients. An engineered adeno-associated virus delivers the genetic instructions in a single administration, after which the patient’s own cells manufacture the antibody continuously. The financing carries VTx-002 through the final readout of PIONEER-ALS, its Phase 1/2 trial, which began dosing in February 2026 in the United States and Europe.
In September, before any efficacy data, VectorY tripled the trial’s planned enrollment from 12 to 36 patients across two dose levels, citing rapid recruitment and site activation. The open-label study’s primary focus is safety and tolerability, with biomarkers including neurofilament light chain and clinical measures such as muscle strength and respiratory function tracked alongside. The company has not disclosed when the final readout will land.
Beyond ALS, the round advances VTx-003, a preclinical program against mutant huntingtin in Huntington’s disease, and earlier work in frontotemporal dementia and Alzheimer’s disease. The structure of the deal is itself a signal: a third of the new money is public development-bank debt, which lowers the dilution cost of a long, binary gene therapy program but does not change its risk. Whether a vectorized antibody can safely clear TDP-43 pathology in humans remains unproven, and PIONEER-ALS, with no placebo arm, will speak first to safety and biomarkers rather than to clinical benefit.